AACR 2021 | REGINA: regorafenib, nivolumab and short-course radiotherapy for rectal cancer

Giacomo Bregni, MD, Jules Bordet Institute, Brussels, Belgium, gives an overview of the Phase II REGINA trial (NCT04503694) which is investigating the use of regorafenib in combination with nivolumab and short-course radiotherapy in patients with intermediate-risk, stage II-III rectal cancer. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.